Phase 3 N=40 Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus
Oral Lichen Planus
Primary: Pain — 0; 4; 4.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,891 CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)
Breast Augmentation · Breast Reconstruction · Breast Revision
Primary: 6-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 8.3; 31.7; 13.8; 31.3 percentage of subjects
Phase 3 N=266 OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement
Otitis Media With Effusion
Primary: Percentage of Participants Who Were Treatment Failures. — 21.3; 45.5 percentage of treatment failures
Phase 3 N=486 Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
Colorectal Cancer
Primary: Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on…
Phase 3 N=15 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
Alopecia
Primary: Hair Density Change After Three Treatments — 175.1 percentage of pre-treatment hair density
Phase 3 N=455 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO) — 59.5; 56.6…
Phase 3 N=58 A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
Rheumatoid Arthritis
Primary: Change From Baseline to Week 4 in Synovitis of the Wrist According to Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) Score — 5.78; -0.88 units on a scale
Phase 3 N=454 Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
HIV · HIV Infections
Primary: Number of Patients With Plasma HIV RNA < 50 Copies/mL — 105; 92; 97 participants
Phase 3 N=478 A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Psoriasis
Primary: The Number of Visits at Which Participants Achieved a Static Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) — 4.5; 4.1 number of visits
Phase 3 N=289 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Post-stroke Spasticity of the Lower Limb
Primary: Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4 — 2.8; 2.8; -0.4; -0.4 Units on a scale — p=0.777
Phase 3 N=60 Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Asthma
Primary: Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20) — 17.70; 9.88; 20.10; 10.78 mg/mL — p=<0.001
Phase 3 N=46 Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Bipolar Disorder · Major Depressive Episode
Primary: SIGH-ADS Depression Score — 10.3; 17.3 units on a scale — p==0.005
Phase 3 N=118 Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients
Fever
Primary: Fever Reduction — -1.5; -0.9 degree Celsius*Time
Phase 3 N=20 A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.
Anemia
Primary: Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy…
Phase 3 N=295 A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
Helminth Infections
Primary: Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period — 11.1; 83.7 percentage of participants — p=< 0.001